Login Register Cart 0
Generic placeholder image

Mini-Reviews in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1389-5575
ISSN (Online): 1875-5607

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

The Role of VD/VDR Signaling Pathway in Autoimmune Skin Diseases

Author(s): Yilan Zeng, Shengbo Yang, Yuanhong Liu, Ziting Tang, Xiule Zong, Xuemei Li and Dan Wang*

Volume 23, Issue 6, 2023

Published on: 27 December, 2022

Page: [652 - 661] Pages: 10

DOI: 10.2174/1389557523666221124123206

Price: $65

Abstract

Background: Immune-related cutaneous diseases are a series of disorders, such as alopecia areata, psoriasis, atopic dermatitis, systemic lupus erythematosus and autoimmune bullous dermatoses. Vitamin D is a fat-soluble vitamin, which is known for its classical pleiotropic effect. Recent studies have found that vitamin D, after catalyzed into its biologically active form [1,25(OH) 2D], correlated with its receptor, vitamin D receptor, plays a vital role in multiple pathophysiological processes, including immune-related dermatoses. This review mainly summarizes evidence on the role of vitamin D/vitamin D receptor in immune-related cutaneous diseases and the potential therapeutic targets for skin disorders.

Methods: We have carried out a comprehensive literature search in PubMed and Google Scholar databases using keywords like “vitamin D”, “vitamin D receptor”, “immune”, “psoriasis”, “atopic dermatitis”, “skin”, “systemic lupus erythematosus”, “alopecia areata” and “autoimmune bullous dermatoses”. Only articles related to the topic were included in this review. Conference, patent, graduation thesis and articles without available full text were excluded.

Results: Vitamin D/vitamin D receptor is critical for skin in regulating the proliferation and differentiation of keratinocytes, keeping the integrity of the skin barrier as well as maintaining the homeostasis of the “skin's immune system”. Vitamin D deficiency/vitamin D receptor mutations are potential risk factors for some immune-related cutaneous diseases.

Conclusion: Vitamin D is a pleiotropic hormone, which is important in the homeostasis of human body. Many studies have revealed vitamin D deficiency in several skin diseases. Thus, vitamin D supplementation may be a useful therapeutic option for immune-related skin diseases.

« Previous Next »
Graphical Abstract

[1]
Gerkowicz, A.; Chyl-Surdacka, K.; Krasowska, D.; Chodorowska, G. The role of vitamin D in non-scarring alopecia. Int. J. Mol. Sci., 2017, 18(12), 2653.
[http://dx.doi.org/10.3390/ijms18122653] [PMID: 29215595]
[2]
Arenberger, P.; Arenbergerova, M. New and current preventive treatment options in actinic keratosis. J. Eur. Acad. Dermatol. Venereol., 2017, 31(S5), 13-17.
[http://dx.doi.org/10.1111/jdv.14375] [PMID: 28805940]
[3]
Mostafa, W.Z.; Hegazy, R.A. Vitamin D and the skin: Focus on a complex relationship: A review. J. Adv. Res., 2015, 6(6), 793-804.
[http://dx.doi.org/10.1016/j.jare.2014.01.011] [PMID: 26644915]
[4]
Charoenngam, N.; Holick, M.F. Immunologic effects of vitamin D on human health and disease. Nutrients, 2020, 12(7), 2097.
[http://dx.doi.org/10.3390/nu12072097] [PMID: 32679784]
[5]
Alhassan Mohammed, H.; Saboor-Yaraghi, A.A.; Mirshafiey, A.; Vahedi, H.; Shiri-Shahsavar, M.R.; Mousavi Nasl Khameneh, A. Immunomodulatory and immunosuppressive roles of 1α, 25(OH)2D3 in autoimmune diseases. Scand. J. Immunol., 2017, 85(2), 95-103.
[http://dx.doi.org/10.1111/sji.12512] [PMID: 27896829]
[6]
Wang, H.; Chen, W.; Li, D.; Yin, X.; Zhang, X.; Olsen, N.; Zheng, S.G. Vitamin D and chronic diseases. Aging Dis., 2017, 8(3), 346-353.
[http://dx.doi.org/10.14336/AD.2016.1021] [PMID: 28580189]
[7]
Jones, G.; Prosser, D.E.; Kaufmann, M. Cytochrome P450-mediated metabolism of vitamin D. J. Lipid Res., 2014, 55(1), 13-31.
[http://dx.doi.org/10.1194/jlr.R031534] [PMID: 23564710]
[8]
Holick, M.F.; Binkley, N.C.; Bischoff-Ferrari, H.A.; Gordon, C.M.; Hanley, D.A.; Heaney, R.P.; Murad, M.H.; Weaver, C.M. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab., 2011, 96(7), 1911-1930.
[http://dx.doi.org/10.1210/jc.2011-0385] [PMID: 21646368]
[9]
Holick, M.F. Vitamin D deficiency. N. Engl. J. Med., 2007, 357(3), 266-281.
[http://dx.doi.org/10.1056/NEJMra070553] [PMID: 17634462]
[10]
Reichrath, J.; Saternus, R.; Vogt, T. Endocrine actions of vitamin D in skin: Relevance for photocarcinogenesis of non-melanoma skin cancer, and beyond. Mol. Cell. Endocrinol., 2017, 453, 96-102.
[http://dx.doi.org/10.1016/j.mce.2017.05.001] [PMID: 28526240]
[11]
Zierold, C.; Nehring, J.A.; Deluca, H.F. Nuclear receptor 4A2 and C/EBPβ regulate the parathyroid hormone-mediated transcriptional regulation of the 25-hydroxyvitamin D3-1 α-hydroxylase. Arch. Biochem. Biophys., 2007, 460(2), 233-239.
[http://dx.doi.org/10.1016/j.abb.2006.11.028] [PMID: 17224121]
[12]
Rost, C.R.; Bikle, D.D.; Kaplan, R.A. In vitro stimulation of 25-hydroxycholecalciferol 1 alpha-hydroxylation by parathyroid hormone in chick kidney slices: Evidence for a role for adenosine 3′,5′-monophosphate. Endocrinology, 1981, 108(3), 1002-1006.
[http://dx.doi.org/10.1210/endo-108-3-1002] [PMID: 6257493]
[13]
Perwad, F.; Azam, N.; Zhang, M.Y.H.; Yamashita, T.; Tenenhouse, H.S.; Portale, A.A. Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. Endocrinology, 2005, 146(12), 5358-5364.
[http://dx.doi.org/10.1210/en.2005-0777] [PMID: 16123154]
[14]
Bakke, D.; Sun, J. Ancient nuclear receptor VDR with new functions: microbiome and inflammation. Inflamm. Bowel Dis., 2018, 24(6), 1149-1154.
[http://dx.doi.org/10.1093/ibd/izy092] [PMID: 29718408]
[15]
Cianferotti, L.; Cox, M.; Skorija, K.; Demay, M.B. Vitamin D receptor is essential for normal keratinocyte stem cell function. Proc. Natl. Acad. Sci., 2007, 104(22), 9428-9433.
[http://dx.doi.org/10.1073/pnas.0702884104] [PMID: 17517646]
[16]
Sasaki, H.; Harada, H.; Handa, Y.; Morino, H.; Suzawa, M.; Shimpo, E.; Katsumata, T.; Masuhiro, Y.; Matsuda, K.; Ebihara, K. Transcriptional activity of a fluorinated vitamin D analog on VDR-RXR-mediated gene expression. Biochemistry, 1995, 34(1), 370-377.
[http://dx.doi.org/10.1021/bi00001a045] [PMID: 7819220]
[17]
Aksu Cerman, A.; Sarikaya Solak, S.; Kivanc Altunay, I. Vitamin D deficiency in alopecia areata. Br. J. Dermatol., 2014, 170(6), 1299-1304.
[http://dx.doi.org/10.1111/bjd.12980] [PMID: 24655364]
[18]
Haussler, M.R.; Whitfield, G.K.; Kaneko, I.; Haussler, C.A.; Hsieh, D.; Hsieh, J.C.; Jurutka, P.W. Molecular mechanisms of vitamin D action. Calcif. Tissue Int., 2013, 92(2), 77-98.
[http://dx.doi.org/10.1007/s00223-012-9619-0] [PMID: 22782502]
[19]
Bikle, D.D. The vitamin D receptor: A tumor suppressor in skin. Adv. Exp. Med. Biol., 2014, 810, 282-302.
[http://dx.doi.org/10.1007/978-1-4939-0437-2_16] [PMID: 25207372]
[20]
Amon, U.; Baier, L.; Yaguboglu, R.; Ennis, M.; Holick, M.F.; Amon, J. Serum 25-hydroxyvitamin D levels in patients with skin diseases including psoriasis, infections, and atopic dermatitis. Dermatoendocrinol, 2018, 10(1), e1442159.
[http://dx.doi.org/10.1080/19381980.2018.1442159] [PMID: 29904567]
[21]
Wei, R.; Christakos, S. Mechanisms underlying the regulation of innate and adaptive immunity by vitamin D. Nutrients, 2015, 7(10), 8251-8260.
[http://dx.doi.org/10.3390/nu7105392] [PMID: 26404359]
[22]
Bartley, J.; Vitamin, D. Emerging roles in infection and immunity. Expert Rev. Anti Infect. Ther., 2010, 8(12), 1359-1369.
[http://dx.doi.org/10.1586/eri.10.102] [PMID: 21133662]
[23]
Medrano, M.; Carrillo-Cruz, E.; Montero, I.; Perez-Simon, J.; Vitamin, D.; Vitamin, D. Effect on haematopoiesis and immune system and clinical applications. Int. J. Mol. Sci., 2018, 19(9), 2663.
[http://dx.doi.org/10.3390/ijms19092663] [PMID: 30205552]
[24]
van Etten, E.; Decallonne, B.; Verlinden, L.; Verstuyf, A.; Bouillon, R.; Mathieu, C. Analogs of 1α, 25-dihydroxyvitamin D3 as pluripotent immunomodulators. J. Cell. Biochem., 2003, 88(2), 223-226.
[http://dx.doi.org/10.1002/jcb.10329] [PMID: 12520518]
[25]
Amento, E.P.; Bhalla, A.K.; Kurnick, J.T.; Kradin, R.L.; Clemens, T.L.; Holick, S.A.; Holick, M.F.; Krane, S.M. 1 alpha,25-dihydroxyvitamin D3 induces maturation of the human monocyte cell line U937, and, in association with a factor from human T lymphocytes, augments production of the monokine, mononuclear cell factor. J. Clin. Invest., 1984, 73(3), 731-739.
[http://dx.doi.org/10.1172/JCI111266] [PMID: 6608530]
[26]
Kongsbak, M.; von Essen, M.R.; Levring, T.B.; Schjerling, P.; Woetmann, A.; Ødum, N.; Bonefeld, C.M.; Geisler, C. Vitamin D-binding protein controls T cell responses to vitamin D. BMC Immunol., 2014, 15(1), 35.
[http://dx.doi.org/10.1186/s12865-014-0035-2] [PMID: 25230725]
[27]
Carvalho, J.T.G.; Schneider, M.; Cuppari, L.; Grabulosa, C.C.; Aoike, D. Q Redublo, B.M.; C Batista, M.; Cendoroglo, M.; Maria Moyses, R.; Dalboni, M.A. Cholecalciferol decreases inflammation and improves vitamin D regulatory enzymes in lymphocytes in the uremic environment: A randomized controlled pilot trial. PLoS One, 2017, 12(6), e0179540.
[http://dx.doi.org/10.1371/journal.pone.0179540] [PMID: 28665937]
[28]
Fawaz, L.; Mrad, M.F.; Kazan, J.M.; Sayegh, S.; Akika, R.; Khoury, S.J. Comparative effect of 25(OH)D3 and 1,25(OH)2D3 on Th17 cell differentiation. Clin. Immunol., 2016, 166-167, 59-71.
[http://dx.doi.org/10.1016/j.clim.2016.02.011] [PMID: 27041081]
[29]
Jeffery, L.E.; Burke, F.; Mura, M.; Zheng, Y.; Qureshi, O.S.; Hewison, M.; Walker, L.S.K.; Lammas, D.A.; Raza, K.; Sansom, D.M. 1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. J. Immunol., 2009, 183(9), 5458-5467.
[http://dx.doi.org/10.4049/jimmunol.0803217] [PMID: 19843932]
[30]
Lemire, J.M.; Adams, J.S.; Sakai, R.; Jordan, S.C. 1 alpha,25-dihydroxyvitamin D3 suppresses proliferation and immunoglobulin production by normal human peripheral blood mononuclear cells. J. Clin. Invest., 1984, 74(2), 657-661.
[http://dx.doi.org/10.1172/JCI111465] [PMID: 6611355]
[31]
Chen, S.; Sims, G.P.; Chen, X.X.; Gu, Y.Y.; Chen, S.; Lipsky, P.E. Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J. Immunol., 2007, 179(3), 1634-1647.
[http://dx.doi.org/10.4049/jimmunol.179.3.1634] [PMID: 17641030]
[32]
Harder, J.; Bartels, J.; Christophers, E.; Schröder, J.M. A peptide antibiotic from human skin. Nature, 1997, 387(6636), 861.
[http://dx.doi.org/10.1038/43088] [PMID: 9202117]
[33]
Wollenberg, A.; Räwer, H.C.; Schauber, J. Innate immunity in atopic dermatitis. Clin. Rev. Allergy Immunol., 2011, 41(3), 272-281.
[http://dx.doi.org/10.1007/s12016-010-8227-x] [PMID: 21181301]
[34]
de Jongh, G.J.; Zeeuwen, P.L.J.M.; Kucharekova, M.; Pfundt, R.; van der Valk, P.G.; Blokx, W.; Dogan, A.; Hiemstra, P.S.; van de Kerkhof, P.C.; Schalkwijk, J. High expression levels of keratinocyte antimicrobial proteins in psoriasis compared with atopic dermatitis. J. Invest. Dermatol., 2005, 125(6), 1163-1173.
[http://dx.doi.org/10.1111/j.0022-202X.2005.23935.x] [PMID: 16354186]
[35]
Matejuk, A. Skin Immunity. Arch. Immunol. Ther. Exp., 2018, 66(1), 45-54.
[http://dx.doi.org/10.1007/s00005-017-0477-3] [PMID: 28623375]
[36]
Manggau, M.; Kim, D.S.; Ruwisch, L.; Vogler, R.; Schäfer-Korting, M.; Kleuser, B.; Korting, H.C. 1Alpha,25-dihydroxyvitamin D3 protects human keratinocytes from apoptosis by the formation of sphingosine-1-phosphate. J. Invest. Dermatol., 2001, 117(5), 1241-1249.
[http://dx.doi.org/10.1046/j.0022-202x.2001.01496.x] [PMID: 11710939]
[37]
Barrea, L.; Savanelli, M.C.; Di Somma, C.; Napolitano, M.; Megna, M.; Colao, A.; Savastano, S. Vitamin D and its role in psoriasis: An overview of the dermatologist and nutritionist. Rev. Endocr. Metab. Disord., 2017, 18(2), 195-205.
[http://dx.doi.org/10.1007/s11154-017-9411-6] [PMID: 28176237]
[38]
Hegyi, Z.; Zwicker, S.; Bureik, D.; Peric, M.; Koglin, S.; Batycka-Baran, A.; Prinz, J.C.; Ruzicka, T.; Schauber, J.; Wolf, R. Vitamin D analog calcipotriol suppresses the Th17 cytokine-induced proinflammatory S100 “alarmins” psoriasin (S100A7) and koebnerisin (S100A15) in psoriasis. J. Invest. Dermatol., 2012, 132(5), 1416-1424.
[http://dx.doi.org/10.1038/jid.2011.486] [PMID: 22402441]
[39]
Psoriasis, L.M. Lancet, 2003, 361(9364), 1197-1204.
[http://dx.doi.org/10.1016/S0140-6736(03)12954-6] [PMID: 12686053]
[40]
Mattozzi, C.; Paolino, G.; Richetta, A.G.; Calvieri, S. Psoriasis, vitamin D and the importance of the cutaneous barrier’s integrity: An update. J. Dermatol., 2016, 43(5), 507-514.
[http://dx.doi.org/10.1111/1346-8138.13305] [PMID: 26971536]
[41]
Trémezaygues, L.; Reichrath, J. Vitamin D analogs in the treatment of psoriasis. Dermatoendocrinol, 2011, 3(3), 180-186.
[http://dx.doi.org/10.4161/derm.17534] [PMID: 22110777]
[42]
Soleymani, T.; Hung, T.; Soung, J. The role of vitamin D in psoriasis: a review. Int. J. Dermatol., 2015, 54(4), 383-392.
[http://dx.doi.org/10.1111/ijd.12790] [PMID: 25601579]
[43]
Armstrong, A.W.; Read, C. Pathophysiology, clinical presentation, and treatment of psoriasis. JAMA, 2020, 323(19), 1945-1960.
[http://dx.doi.org/10.1001/jama.2020.4006] [PMID: 32427307]
[44]
Kerkhof, P.C.M. Biological activity of vitamin D analogues in the skin, with special reference to antipsoriatic mechanisms. Br. J. Dermatol., 1995, 132(5), 675-682.
[http://dx.doi.org/10.1111/j.1365-2133.1995.tb00710.x] [PMID: 7772470]
[45]
Peric, M.; Koglin, S.; Dombrowski, Y.; Groß, K.; Bradac, E.; Büchau, A.; Steinmeyer, A.; Zügel, U.; Ruzicka, T.; Schauber, J. Vitamin D analogs differentially control antimicrobial peptide/“alarmin” expression in psoriasis. PLoS One, 2009, 4(7), e6340.
[http://dx.doi.org/10.1371/journal.pone.0006340] [PMID: 19623255]
[46]
Hau, C.S.; Shimizu, T.; Tada, Y.; Kamata, M.; Takeoka, S.; Shibata, S.; Mitsui, A.; Asano, Y.; Sugaya, M.; Kadono, T.; Sato, S.; Watanabe, S. The vitamin D3 analog, maxacalcitol, reduces psoriasiform skin inflammation by inducing regulatory T cells and downregulating IL-23 and IL-17 production. J. Dermatol. Sci., 2018, 92(2), 117-126.
[http://dx.doi.org/10.1016/j.jdermsci.2018.08.007] [PMID: 30166055]
[47]
Ingram, M.A.; Jones, M.B.; Stonehouse, W.; Jarrett, P.; Scragg, R.; Mugridge, O.; von Hurst, P.R. Oral vitamin D3 supplementation for chronic plaque psoriasis: A randomized, double-blind, placebo-controlled trial. J. Dermatolog. Treat., 2018, 29(7), 648-657.
[http://dx.doi.org/10.1080/09546634.2018.1444728] [PMID: 29480035]
[48]
Guo, H.; Cheng, Y.; Shapiro, J.; McElwee, K. The role of lymphocytes in the development and treatment of alopecia areata. Expert Rev. Clin. Immunol., 2015, 11(12), 1335-1351.
[http://dx.doi.org/10.1586/1744666X.2015.1085306] [PMID: 26548356]
[49]
Simakou, T.; Butcher, J.P.; Reid, S.; Henriquez, F.L. Alopecia areata: A multifactorial autoimmune condition. J. Autoimmun., 2019, 98, 74-85.
[http://dx.doi.org/10.1016/j.jaut.2018.12.001] [PMID: 30558963]
[50]
Lin, X.; Meng, X.; Song, Z. Vitamin D and alopecia areata: possible roles in pathogenesis and potential implications for therapy. Am. J. Transl. Res., 2019, 11(9), 5285-5300.
[PMID: 31632510]
[51]
Fawzi, M.M.T.; Mahmoud, S.B.; Ahmed, S.F.; Shaker, O.G. Assessment of vitamin D receptors in alopecia areata and androgenetic alopecia. J. Cosmet. Dermatol., 2016, 15(4), 318-323.
[http://dx.doi.org/10.1111/jocd.12224] [PMID: 27151518]
[52]
Bakry, O.; El Farargy, S.; El Shafiee, M.; Soliman, A. Serum Vitamin D in patients with alopecia areata. Indian Dermatol. Online J., 2016, 7(5), 371-377.
[http://dx.doi.org/10.4103/2229-5178.190504] [PMID: 27730032]
[53]
Tsa, i T.Y.; Huang, Y.C. Vitamin D deficiency in patients with alopecia areata: A systematic review and meta-analysis. J. Am. Acad. Dermatol., 2018, 78(1), 207-209.
[http://dx.doi.org/10.1016/j.jaad.2018.03.058] [PMID: 29753060]
[54]
Thompson, J.M.; Li, T.; Park, M.K.; Qureshi, A.A.; Cho, E. Estimated serum vitamin D status, vitamin D intake, and risk of incident alopecia areata among US women. Arch. Dermatol. Res., 2016, 308(9), 671-676.
[http://dx.doi.org/10.1007/s00403-016-1687-y] [PMID: 27664090]
[55]
Lee, S.; Kim, B.J.; Lee, C.H.; Lee, W.S. Increased prevalence of vitamin D deficiency in patients with alopecia areata: A systematic review and meta-analysis. J. Eur. Acad. Dermatol. Venereol., 2018, 32(7), 1214-1221.
[http://dx.doi.org/10.1111/jdv.14987] [PMID: 29633370]
[56]
Kim, D.H.; Lee, J.W.; Kim, I.S.; Choi, S.Y.; Lim, Y.Y.; Kim, H.M.; Kim, B.J.; Kim, M.N. Successful treatment of alopecia areata with topical calcipotriol. Ann. Dermatol., 2012, 24(3), 341-344.
[http://dx.doi.org/10.5021/ad.2012.24.3.341] [PMID: 22879719]
[57]
Çerman, A.A.; Solak, S.S. Altunay, İ; Küçükünal, N.A. Topical calcipotriol therapy for mild-to-moderate alopecia areata: a retrospective study. J. Drugs Dermatol., 2015, 14(6), 616-620.
[PMID: 26091388]
[58]
Narang, T.; Daroach, M.; Kumaran, M.S. Efficacy and safety of topical calcipotriol in management of alopecia areata: A pilot study. Dermatol. Ther. , 2017, 30(3), e12464.
[http://dx.doi.org/10.1111/dth.12464] [PMID: 28133875]
[59]
Bieber, T. Atopic dermatitis. N. Engl. J. Med., 2008, 358(14), 1483-1494.
[http://dx.doi.org/10.1056/NEJMra074081] [PMID: 18385500]
[60]
Schlichte, M.; Vandersall, A.; Katta, R. Diet and eczema: a review of dietary supplements for the treatment of atopic dermatitis. Dermatol. Pract. Concept., 2016, 6(3), 23-29.
[http://dx.doi.org/10.5826/dpc.0603a06] [PMID: 27648380]
[61]
Hattangdi-Haridas, S.R.; Lanham-New, S.A.; Wong, W.H.S.; Ho, M.H.K.; Darling, A.L.; Vitamin, D. Vitamin D deficiency and effects of vitamin d supplementation on disease severity in patients with atopic dermatitis: A systematic review and meta-analysis in adults and children. Nutrients, 2019, 11(8), 1854.
[http://dx.doi.org/10.3390/nu11081854] [PMID: 31405041]
[62]
Huang, Y.H.; Yang, T.H.; Huang, P.C.; Chen, Y.K.; Huang, L.T. Low vitamin D levels in breast milk may be a risk factor for atopic dermatitis flare-up during infancy. Dermatitis, 2021, 32(6), e124-e125.
[http://dx.doi.org/10.1097/DER.0000000000000695] [PMID: 33332866]
[63]
Kim, M.; Kim, S.N.; Lee, Y.; Choe, Y.; Ahn, K.; Vitamin, D. Vitamin D status and efficacy of vitamin d supplementation in atopic dermatitis: a systematic review and meta-analysis. Nutrients, 2016, 8(12), 789.
[http://dx.doi.org/10.3390/nu8120789] [PMID: 27918470]
[64]
Heine, G.; Hoefer, N.; Franke, A.; Nöthling, U.; Schumann, R.R.; Hamann, L.; Worm, M. Association of vitamin D receptor gene polymorphisms with severe atopic dermatitis in adults. Br. J. Dermatol., 2013, 168(4), 855-858.
[http://dx.doi.org/10.1111/bjd.12077] [PMID: 23034014]
[65]
Camargo, C.A., Jr; Ganmaa, D.; Sidbury, R.; Erdenedelger, K.; Radnaakhand, N.; Khandsuren, B. Randomized trial of vitamin D supplementation for winter-related atopic dermatitis in children. J. Allergy Clin. Immunol., 2014, 134(4), 831-835.e1.
[http://dx.doi.org/10.1016/j.jaci.2014.08.002] [PMID: 25282565]
[66]
El-Heis, S.; D’Angelo, S.; Curtis, E.M.; Healy, E.; Moon, R.J.; Crozier, S.R.; Inskip, H.; Cooper, C.; Harvey, N.C.; Godfrey, K.M. Maternal antenatal vitamin D supplementation and offspring risk of atopic eczema in the first 4 years of life: evidence from a randomized controlled trial. Br. J. Dermatol., 2022, bjd.21721.
[http://dx.doi.org/10.1111/bjd.21721] [PMID: 35763390]
[67]
Yang, L.; Sato, M.; Saito-Abe, M.; Nishizato, M.; Mezawa, H.; Yamamoto-Hanada, K.; Ohya, Y. Serum 25-hydroxyvitamin D concentrations and atopic dermatitis in early childhood: Findings from the japan environment and children’s study. Nutrients, 2021, 13(8), 2761.
[http://dx.doi.org/10.3390/nu13082761] [PMID: 34444921]
[68]
Lara-Corrales, I.; Huang, C.M.; Parkin, P.C.; Rubio-Gomez, G.A.; Posso-De Los Rios, C.J.; Maguire, J.; Pope, E. Vitamin D level and supplementation in pediatric atopic dermatitis: A randomized controlled trial. J. Cutan. Med. Surg., 2019, 23(1), 44-49.
[http://dx.doi.org/10.1177/1203475418805744] [PMID: 30336685]
[69]
Tian, Y.; Ye, Y.; Zhang, Y.; Dou, L.; Dou, Y.; Zhao, P.; Jiang, Y.; Gao, X.; Zhang, X.; Huang, J.; Xiao, L.; Wang, L.; Yan, W. Maternal serum 25‐hydroxyvitamin D levels and infant atopic dermatitis: A prospective cohort study. Pediatr. Allergy Immunol., 2021, 32(8), 1637-1645.
[http://dx.doi.org/10.1111/pai.13582] [PMID: 34165218]
[70]
Iruretagoyena, M.; Hirigoyen, D.; Naves, R.; Burgos, P.I. Immune response modulation by vitamin D: Role in systemic lupus erythematosus. Front. Immunol., 2015, 6, 513.
[http://dx.doi.org/10.3389/fimmu.2015.00513] [PMID: 26528285]
[71]
Islam, M.A.; Khandker, S.S.; Alam, S.S.; Kotyla, P.; Hassan, R. Vitamin D status in patients with Systemic Lupus Erythematosus (SLE): A systematic review and meta-analysis. Autoimmun. Rev., 2019, 18(11), 102392.
[http://dx.doi.org/10.1016/j.autrev.2019.102392] [PMID: 31520805]
[72]
Borba, V.Z.C.; Vieira, J.G.H.; Kasamatsu, T.; Radominski, S.C.; Sato, E.I.; Lazaretti-Castro, M. Vitamin D deficiency in patients with active systemic lupus erythematosus. Osteoporos. Int., 2009, 20(3), 427-433.
[http://dx.doi.org/10.1007/s00198-008-0676-1] [PMID: 18600287]
[73]
Aranow, C.; Kamen, D.L.; Dall’Era, M.; Massarotti, E.M.; Mackay, M.C.; Koumpouras, F.; Coca, A.; Chatham, W.W.; Clowse, M.E.B.; Criscione-Schreiber, L.G.; Callahan, S.; Goldmuntz, E.A.; Keyes-Elstein, L.; Oswald, M.; Gregersen, P.K.; Diamond, B. Randomized, double-blind, placebo-controlled trial of the effect of vitamin D 3 on the interferon signature in patients with systemic lupus erythematosus. Arthritis Rheumatol., 2015, 67(7), 1848-1857.
[http://dx.doi.org/10.1002/art.39108] [PMID: 25777546]
[74]
Hayashi, K.; Sada, K.E.; Asano, Y.; Katayama, Y.; Ohashi, K.; Morishita, M.; Miyawaki, Y.; Watanabe, H.; Katsuyama, T.; Narazaki, M.; Matsumoto, Y.; Yajima, N.; Yoshimi, R.; Shimojima, Y.; Ohno, S.; Kajiyama, H.; Ichinose, K.; Sato, S.; Fujiwara, M.; Wada, J. Real-world data on vitamin D supplementation and its impacts in systemic lupus erythematosus: Cross-sectional analysis of a lupus registry of nationwide institutions (LUNA). PLoS One, 2022, 17(6), e0270569.
[http://dx.doi.org/10.1371/journal.pone.0270569] [PMID: 35767524]
[75]
Abou-Raya, A.; Abou-Raya, S.; Helmii, M. The effect of vitamin D supplementation on inflammatory and hemostatic markers and disease activity in patients with systemic lupus erythematosus: A randomized placebo-controlled trial. J. Rheumatol., 2013, 40(3), 265-272.
[http://dx.doi.org/10.3899/jrheum.111594] [PMID: 23204220]
[76]
Zheng, R.; Gonzalez, A.; Yue, J.; Wu, X.; Qiu, M.; Gui, L.; Zhu, S.; Huang, L. Efficacy and safety of vitamin D supplementation in patients with systemic lupus erythematosus: A meta-analysis of randomized controlled trials. Am. J. Med. Sci., 2019, 358(2), 104-114.
[http://dx.doi.org/10.1016/j.amjms.2019.04.020] [PMID: 31331447]
[77]
Antico, A.; Tampoia, M.; Tozzoli, R.; Bizzaro, N. Can supplementation with vitamin D reduce the risk or modify the course of autoimmune diseases? A systematic review of the literature. Autoimmun. Rev., 2012, 12(2), 127-136.
[http://dx.doi.org/10.1016/j.autrev.2012.07.007] [PMID: 22776787]
[78]
Yancey, K.B.; Egan, C.A. Pemphigoid: clinical, histologic, immunopathologic, and therapeutic considerations. JAMA, 2000, 284(3), 350-356.
[http://dx.doi.org/10.1001/jama.284.3.350] [PMID: 10891967]
[79]
Hertl, M.; Eming, R.; Veldman, C. T cell control in autoimmune bullous skin disorders. J. Clin. Invest., 2006, 116(5), 1159-1166.
[http://dx.doi.org/10.1172/JCI28547] [PMID: 16670756]
[80]
Yang, M.; Wu, H.; Zhao, M.; Long, H.; Lu, Q. Vitamin D status in patients with autoimmune bullous dermatoses: a meta-analysis. J. Dermatolog. Treat., 2022, 33(3), 1356-1367.
[http://dx.doi.org/10.1080/09546634.2020.1810606] [PMID: 32799714]
[81]
Sarre, M.E.; Riou, J.; Duval, G.T.; Martin, L.; Annweiler, C. Association between serum 25-hydroxyvitamin D concentration and severity of first-diagnosed bullous pemphigoid in older adults. Arch. Gerontol. Geriatr., 2019, 83, 28-30.
[http://dx.doi.org/10.1016/j.archger.2019.03.015] [PMID: 30933743]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy